Do analysts rate AIXC or BTMD?

biote has a consensus price target of $2.75, suggesting a potential upside of 21.95%. Given biote's stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media favor AIXC or BTMD?

In the previous week, biote had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for biote and 3 mentions for Qualigen Therapeutics. biote's average media sentiment score of 1.37 beat Qualigen Therapeutics' score of 0.06 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral biote 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer HRTX or AIXC?

Heron Therapeutics currently has a consensus target price of $2.50, suggesting a potential upside of 495.24%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to HRTX or AIXC?

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Qualigen Therapeutics and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.08 beat Qualigen Therapeutics' score of 0.06 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AIXC or ENTX?

Entera Bio has a consensus price target of $9.00, indicating a potential upside of 435.08%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts clearly believe Entera Bio is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is AIXC or ENTX more profitable?

Entera Bio's return on equity of -83.31% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% Entera Bio N/A -83.31% -70.83%

Does the media prefer AIXC or ENTX?

In the previous week, Entera Bio had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for Entera Bio and 3 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.06 beat Entera Bio's score of -0.13 indicating that Qualigen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Entera Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer AIXC or RLYB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to AIXC or RLYB?

In the previous week, Qualigen Therapeutics and Qualigen Therapeutics both had 3 articles in the media. Rallybio's average media sentiment score of 0.88 beat Qualigen Therapeutics' score of 0.06 indicating that Rallybio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Rallybio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RNTX or AIXC?

Rein Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 651.07%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Rein Therapeutics is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, RNTX or AIXC?

Rein Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rein Therapeutics N/A N/A -$49.87M -$1.90 N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is RNTX or AIXC more profitable?

Rein Therapeutics' return on equity of 0.00% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A N/A -68.14% Qualigen Therapeutics N/A -771.52% -79.52%

Does the media prefer RNTX or AIXC?

In the previous week, Rein Therapeutics had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for Rein Therapeutics and 3 mentions for Qualigen Therapeutics. Rein Therapeutics' average media sentiment score of 0.89 beat Qualigen Therapeutics' score of 0.06 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Qualigen Therapeutics (AIXC) Competitors

$1.01 +0.02 (+1.90%)

As of 12:26 PM Eastern

Compare

AIXC vs. BTMD, HRTX, ENTX, RLYB, and RNTX

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include biote (BTMD), Heron Therapeutics (HRTX), Entera Bio (ENTX), Rallybio (RLYB), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry.

How does Qualigen Therapeutics compare to biote?

Qualigen Therapeutics (NASDAQ:AIXC) and biote (NASDAQ:BTMD) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by insiders. Comparatively, 32.4% of biote shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, biote had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for biote and 3 mentions for Qualigen Therapeutics. biote's average media sentiment score of 1.37 beat Qualigen Therapeutics' score of 0.06 indicating that biote is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
biote	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

biote has higher revenue and earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
biote	$192.22M	0.44	$27.05M	$0.44	5.13

biote has a consensus price target of $2.75, suggesting a potential upside of 21.95%. Given biote's stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Qualigen Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, biote has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

biote has a net margin of 8.29% compared to Qualigen Therapeutics' net margin of 0.00%. biote's return on equity of -25.72% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
biote	8.29%	-25.72%	15.12%

Summary

biote beats Qualigen Therapeutics on 16 of the 16 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Qualigen Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Qualigen Therapeutics' return on equity of -771.52% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Heron Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Heron Therapeutics currently has a consensus target price of $2.50, suggesting a potential upside of 495.24%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.51	-$20.19M	-$0.18	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Qualigen Therapeutics and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.08 beat Qualigen Therapeutics' score of 0.06 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Heron Therapeutics beats Qualigen Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Entera Bio?

Qualigen Therapeutics (NASDAQ:AIXC) and Entera Bio (NASDAQ:ENTX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Entera Bio has higher revenue and earnings than Qualigen Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Entera Bio	$40K	2,072.64	-$11.44M	-$0.27	N/A

Entera Bio's return on equity of -83.31% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Entera Bio	N/A	-83.31%	-70.83%

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 10.6% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Entera Bio has a consensus price target of $9.00, indicating a potential upside of 435.08%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts clearly believe Entera Bio is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Entera Bio had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for Entera Bio and 3 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.06 beat Entera Bio's score of -0.13 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entera Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Qualigen Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Summary

Entera Bio beats Qualigen Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Rallybio?

Qualigen Therapeutics (NASDAQ:AIXC) and Rallybio (NASDAQ:RLYB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 10.3% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Qualigen Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Rallybio	-911.07%	-55.79%	-51.48%

In the previous week, Qualigen Therapeutics and Qualigen Therapeutics both had 3 articles in the media. Rallybio's average media sentiment score of 0.88 beat Qualigen Therapeutics' score of 0.06 indicating that Rallybio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rallybio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rallybio has higher revenue and earnings than Qualigen Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Rallybio	$860K	99.70	-$8.98M	-$4.34	N/A

Qualigen Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market.

Summary

Rallybio beats Qualigen Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Rein Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Rein Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

Rein Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 651.07%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Rein Therapeutics is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Rein Therapeutics had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for Rein Therapeutics and 3 mentions for Qualigen Therapeutics. Rein Therapeutics' average media sentiment score of 0.89 beat Qualigen Therapeutics' score of 0.06 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rein Therapeutics' return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-68.14%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Summary

Rein Therapeutics beats Qualigen Therapeutics on 11 of the 13 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIXC vs. The Competition

Export

Metric	Qualigen Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$20.42M	$934.40M	$4.39B	$12.62B
Dividend Yield	N/A	4.84%	30.61%	8.43%
P/E Ratio	-0.16	1.55	23.74	24.39
Price / Sales	N/A	116.68	143.58	91.34
Price / Cash	N/A	20.06	165.47	59.39
Price / Book	-1.35	8.59	12.35	6.31
Net Income	-$16.97M	-$3.40M	$120.20M	$331.45M
7 Day Performance	-3.90%	-1.75%	-0.76%	0.26%
1 Month Performance	-26.35%	-0.85%	-2.84%	-0.64%
1 Year Performance	N/A	35.18%	11.32%	20.24%

Qualigen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIXC Qualigen Therapeutics	0.1545 of 5 stars	$1.01 +1.9%	N/A	N/A	$20.42M	N/A	N/A	50	Short Interest Increase
BTMD biote	4.6799 of 5 stars	$2.26 +0.4%	$2.75 +21.7%	-45.8%	$84.93M	$192.22M	5.14	194	News Coverage Short Interest Decrease
HRTX Heron Therapeutics	2.3051 of 5 stars	$0.45 +4.7%	$2.50 +461.2%	-79.7%	$84.32M	$154.90M	N/A	300	News Coverage Positive News
ENTX Entera Bio	1.8688 of 5 stars	$1.69 +1.8%	$9.00 +432.5%	-10.0%	$83.30M	N/A	N/A	20	Short Interest Increase
RLYB Rallybio	0.8746 of 5 stars	$15.68 +0.1%	N/A	+376.5%	$83.10M	$860K	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIXC) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qualigen Therapeutics (AIXC) Competitors

AIXC vs. BTMD, HRTX, ENTX, RLYB, and RNTX

How does Qualigen Therapeutics compare to biote?

Summary

How does Qualigen Therapeutics compare to Heron Therapeutics?

Summary

How does Qualigen Therapeutics compare to Entera Bio?

Summary

How does Qualigen Therapeutics compare to Rallybio?

Summary

How does Qualigen Therapeutics compare to Rein Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIXC vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qualigen Therapeutics (AIXC) Competitors

AIXC vs. BTMD, HRTX, ENTX, RLYB, and RNTX

How does Qualigen Therapeutics compare to biote?

Do insiders and institutionals have more ownership in AIXC or BTMD?

Does the media favor AIXC or BTMD?

Which has better valuation & earnings, AIXC or BTMD?

Do analysts rate AIXC or BTMD?

Which has more risk and volatility, AIXC or BTMD?

Is AIXC or BTMD more profitable?

Summary

How does Qualigen Therapeutics compare to Heron Therapeutics?

Is HRTX or AIXC more profitable?

Do institutionals & insiders believe in HRTX or AIXC?

Which has more volatility & risk, HRTX or AIXC?

Do analysts prefer HRTX or AIXC?

Which has stronger earnings and valuation, HRTX or AIXC?

Does the media refer more to HRTX or AIXC?

Summary

How does Qualigen Therapeutics compare to Entera Bio?

Which has better earnings & valuation, AIXC or ENTX?

Is AIXC or ENTX more profitable?

Do insiders & institutionals believe in AIXC or ENTX?

Do analysts recommend AIXC or ENTX?

Does the media prefer AIXC or ENTX?

Which has more volatility and risk, AIXC or ENTX?

Summary

How does Qualigen Therapeutics compare to Rallybio?

Do analysts prefer AIXC or RLYB?

Do insiders and institutionals hold more shares of AIXC or RLYB?

Is AIXC or RLYB more profitable?

Does the media refer more to AIXC or RLYB?

Which has better earnings & valuation, AIXC or RLYB?

Which has more volatility & risk, AIXC or RLYB?

Summary

How does Qualigen Therapeutics compare to Rein Therapeutics?

Which has more risk and volatility, RNTX or AIXC?

Which has higher valuation & earnings, RNTX or AIXC?

Do analysts recommend RNTX or AIXC?

Does the media prefer RNTX or AIXC?

Do insiders and institutionals believe in RNTX or AIXC?

Is RNTX or AIXC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIXC vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools